RT Journal Article
T1 Health Economic Evaluation of Lung Cancer Screening Using a Diagnostic Blood Test: The Early Detection of Cancer of the Lung Scotland (ECLS)
A1 Robles-Zurita, José Antonio
A1 McMeekin, Nicola
A1 Sullivan, Frank
A1 Mair, Frances S.
A1 Briggs, Andrew
K1 Análisis coste-beneficio
AB Background: Diagnostic blood tests have the potential to identify lung cancer in peopleat high risk. We assessed the cost-effectiveness of a lung cancer screening intervention, using theEarlyCDT®-Lung Test (ECLS) with subsequent X-ray and low-dose chest CT scans (LDCT) forpatients with a positive test result, compared to both usual care and LDCT screening for the targetpopulation. Methods: We conducted a model-based lifetime analysis from a UK NHS and personalsocial services perspective. We estimated incremental net monetary benefit (NMB) for the ECLSintervention compared to no screening and to LDCT screening. Results: The incremental NMB ofECLS intervention compared to no screening was GBP 33,179 (95% CI: −GBP 81,396, GBP 147,180)and GBP 140,609 (95% CI: −GBP 36,255, GBP 316,612), respectively, for a cost-effectiveness thresholdof GBP 20,000 and GBP 30,000 per quality-adjusted life year. The same figures compared with LDCTscreening were GBP 162,095 (95% CI: GBP 52,698, GBP 271,735) and GBP 52,185 (95% CI: −GBP115,152, GBP 219,711). Conclusions: The ECLS intervention is the most cost-effective screeningalternative, with the highest probability of being cost-effective, when compared to no screening orLDCT screening. This result may change with modifications of the parameters, suggesting that thethree alternatives considered in the main analysis are potentially cost-effective.
PB MDPI
YR 2024
FD 2024-06-18
LK https://hdl.handle.net/10630/36641
UL https://hdl.handle.net/10630/36641
LA eng
NO Health Economic Evaluation of Lung Cancer Screening Using a Diagnostic Blood Test: The Early Detection of Cancer of the Lung Scotland (ECLS). Curr. Oncol. 2024, 31, 3546–3562. https://doi.org/ 10.3390/curroncol31060261
NO Funding for the ECLS study was received from Oncimmune Ltd. and the Scottish GovernmentHealth & Social Care Directorate of the Chief Scientist Office (CSO).
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 21 ene 2026